Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.
These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts, with a 67% disease control rate in cohort 3.
There were signs of continued clinical activity observed in two patients, one with stage IV gastroesophageal junction cancer and one with stage IV breast cancer. Both patients in cohort 3 show stable disease at their first and second scans.
A patient from cohort 2 with stage IVb metastatic gastric cancer continues to derive clinical benefit after having an observed partial response. The two other patients within cohort 2 continue to show clinical benefit with stable disease, with no change in tumour measurements compared to baseline at over three months.
Benjamin L Schlechter, GI Medical Oncologist at Dana-Farber Cancer Institute, and an investigator on the TACTIC-2 study, said, “These updated interim data showed compelling responses in cancer patients treated with TAC01-HER2. Patients entered the study with refractory disease and were a heavily pre-treated population that had experienced multiple lines of prior therapies.
“The interim safety and efficacy data show that TAC01-HER2 could potentially improve the lives of cancer patients with significant unmet medical need.”
TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognises HER2.
